Category Archives: "INforMS"

Genentech announces new Ocrevus (Ocrelizumab) data for PPMS
Dear Advocates, We are pleased to announce that new OCREVUS® (ocrelizumab) data will be presented at the 4th Congress of the European [...]
AAN publishes guideline on disease-modifying therapies for multiple sclerosis
The AAN published a new guideline, Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis, in Neurology® [...]
New Ocrevus (Ocrelizumab) data demonstrate reductions In activity & progression In RMS
We are pleased to announce that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual [...]
Phase III data in the lancet show Novartis outcomes in secondary progressive multiple sclerosis
EAST HANOVER, N.J., March 22, 2018 – Novartis today announced that the full results from the Phase III EXPAND study of oral, [...]
Abbvie and Biogen pull multiple sclerosis drug Zinbryta following urgent EMA safety review
Seven of the cases were identified in Germany and one in Spain, and included encephalitis and meningoencephalitis. The pharma pair said in [...]
CVS/Aetna combo a formidable pharma rival when it comes to access
Last month's unusual consolidation of healthcare provider CVS Health with insurance company Aetna spawned a new behemoth that could pose a [...]
Fruits and vegetables may help reduce symptoms of multiple sclerosis: study
Eating a healthy diet containing loads of fruits and vegetables along with whole grains may lower disability and reduce symptoms of [...]
Increased epilepsy risk identified in multiple sclerosis
A direct correlation exists between the presence and severity of multiple sclerosis (MS) and the risk for epilepsy, according to study [...]
National Multiple Sclerosis Society endorses multiple sclerosis “NARCRMS” data registry
NEW YORK, Dec. 4, 2017 /PRNewswire-USNewswire/ -- The National Multiple Sclerosis Society is proud to announce its endorsement of [...]
Mayo Clinic develops test to distinguish other demyelinating diseases from multiple sclerosis
The Mayo Clinic has developed a test that allows doctors to distinguish other inflammatory demyelinating diseases from multiple sclerosis [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last